Print  |  Close

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Active: No
Cancer Type: Unknown Primary NCT ID: NCT02658890
Trial Phases: Phase I
Phase II 		Protocol IDs: CA017-003 (primary)
NCI-2016-00153
2015-004914-79
Eligibility: 18 - 100 Years, Male and Female Study Type: Treatment
Study Sponsor: Bristol-Myers Squibb
NCI Full Details: http://clinicaltrials.gov/show/NCT02658890

Summary

The purpose of the study is to determine safety and effectiveness of experimental medication
BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab
in patients with cancers that are advanced or have spread. Pharmacokinetics and
pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab
and Ipilimumab in this patient population will also be assessed.

Treatment Sites in Georgia

Georgia Cancer Specialists - CenterPointe
1100 Johnson Ferry Road
Suite 600
Sandy Springs, GA 30342
404-256-4777 ext 9242
www.gacancer.com



Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

Study Coordinator:
Anila Lokhandwala
404-256-4777 x9242
Doctors:


**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.